DynPort Vaccine Company (DVC), a subsidiary of IT services and solutions company CSC, has signed a follow-on contract with National Institute of Allergy and Infectious Diseases (NIAID), US, a part of the National Institutes of Health. The contract, valued at $90 million, is for 10 years and will require the company to support and conduct Phase 1 clinical trials of infectious disease therapeutics.
Under the agreement, DVC and partners — Quintiles, Health Decisions and WCCT Global — will support and manage Phase 1 clinical trials to assess the safety of therapeutical products taken up for study by NIAID. Besides clinical trials of therapeutical products for infectious diseases DVC will also investigate products, including those to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens.
As the prime contractor, DVC will manage overall program and clinical operations, quality assurance and co-development of protocols and concepts for NIAID.